Discovery of potent macrocyclic HCV NS5A inhibitors.

Bioorganic & Medicinal Chemistry Letters(2016)

Cited 10|Views49
No score
Abstract
HCV NS5A inhibitors have demonstrated impressive in vitro virologic profiles in HCV replicon assays and robust HCV RNA titer reduction in the clinic making them attractive components for inclusion in an all oral fixed-dose combination (FDC) regimen for the treatment of HCV infection. Merck’s effort in this area identified MK-4882 and MK-8325 as early development leads. Herein, we describe the discovery of potent macrocyclic NS5A inhibitors bearing the MK-8325 or MK-4882 core structure.
More
Translated text
Key words
NLVCCEMTGWHLOA-LJADHVKFSA-N,QKFUCROVTLGTAV-VOIOCNMVSA-N,RKBPUMYHWWZKSP-SMHXBLBLSA-N,YRBZTHLCSGOPIL-XLDGMLQKSA-N,MJFMZTAINPXBIP-RRXVSGGESA-N,XEUNGPJLHDBDLL-FBJYALBDSA-N,IHWFCBNZRRITRU-BBACVFHCSA-N,YJEVTLMDXNGQOV-BBACVFHCSA-N,DVNZPVWITWXALC-BBACVFHCSA-N,IDZUPWJBSHAPTE-GTKRZRNESA-N,JWYKQMNINTXCHA-LFQBJWFLSA-N,GEGMQEJODXOPEI-TWAWQFONSA-N,AHJAYNBUBVVINA-RHSNAWLOSA-N,YGCPVRARICYHGL-ZRGVHIMMSA-N,ONHJYMFIFUQFEP-HZWDEHNZSA-N,KJKGYZIRLQRCHG-IIFAZUGRSA-N,DFZNYDFEIFBZRL-ZYADHFCISA-N,UURCRTHCYYILBT-ZQWQDMLBSA-N,XQCMJBLAMHLRKJ-MLSBLXOHSA-N
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined